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Context: With advances in the treatment of congenital hypothyroidism (CH), the neuropsycho-
logical functioning of CH patients is considerably improved. Although much is written about
cognitive and motor development, little is known about emotional and social consequences for
patients growing up with CH, diagnosed by neonatal screening.
Objectives: The objectives of the study were to: 1) compare health-related quality of life (HRQoL),
developmental milestones also called course of life (CoL), sociodemographical outcomes, and
self-esteemof CHpatientswith the general population; and 2) explorewhether severity of CHwas
related to these outcomes.
Design/Setting/Patients:Atotalof69youngadultswithCH,born inTheNetherlands in1981–1982,
completed the “TNO-AZL Questionnaire for Adult’s Health related Quality of Life” questionnaire,
the CoL survey (developmental milestones and sociodemographical outcomes), and a self-esteem
questionnaire.
Main OutcomeMeasures: HRQoL, CoL, social demographical outcomes, and self-esteem in young
adults with CH were determined.
Results: CH patients are more often at risk for HRQoL impairment and reported lower HRQoL on
several domains (cognitive functioning, P  0.0001; sleeping, P  0.004; pain, P  0.0001; daily
activities, P  0.004; vitality, P  0.0001; aggressiveness, P  0.0001; and depressive moods, P 
0.0001) compared with healthy adults. Patients reported a lower self-esteem (P 0.005) and had
a delayed CoL on the domain of social development (P 0.016). There were no significant within-
group differences between the severity groups for HRQoL, CoL, and self-esteem.
Conclusions: Negative consequences in terms of HRQoL, development, and self-esteem are prev-
alent in young adults with CH. Health care physicians should be attentive to these consequences
and provide additional support (emotional and educational guidance) if necessary. (J Clin Endo-
crinol Metab 93: 2654–2661, 2008)
Congenital hypothyroidism (CH) is characterized by the in-sufficient production of thyroid hormone usually due to
thyroid dysgenesis or thyroid dyshormonogenesis. Therefore,
lifelong treatment with T4 is of utmost importance because thy-
roidhormonenotonlyplays an important role inmetabolismbut
also plays amajor role in the development of the central nervous
system during prenatal life and the first years after birth (1). The
aim of neonatal CH screening programs is to prevent cerebral
damage through early initiation of T4 supplementation.
Early treatment has resulted in remarkable improvement in
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the neuropsychological functioning of CH patients (2–4). Nev-
ertheless, there is ample evidence that CH patients diagnosed by
neonatal screening, especially those with severe CH, are still vul-
nerable to persistent cognitive and motor deficits (5–10).
Although much is written about the cognitive and motor de-
velopment of children with CH, little is known about the daily
functioning and quality of life of patients growing up with CH
(11).CHmayaffect the patient’s daily life because of the hospital
visits, daily T4 administration, need of regular dose adjustments,
and sometimes the need of adjuvant medical care such as speech
training and physiotherapy. In addition to this, the cognitive and
motor problems of CH patients might affect their social life,
self-esteem, and emotional functioning.
In general literature, there is growing attention for possible
late psychological effects in children and young adults with
chronic diseases (12). However, the adjustment of young
adults with CH, such as health-related quality of life
(HRQoL), developmental tasks, and self-esteem, has not been
studied thoroughly. HRQoL can be used as an indicator of
adjustment, which comprises elements of physical, functional,
social and psychological health, as well as the patient’s per-
ceived health status and well-being (13). The fulfilling of age-
specific developmental tasks and achieving developmental
milestones in youth, such as searching for contacts outside the
family, or acquisition of independence, referred to as the
“course of life” (CoL), are of great importance to adjustment
in adult life (14). A positive self-esteem is a significant factor
influencing overall good mental health and psychological
well-being (15, 16), and is regarded by major theorists as a
basic psychological need (17).
From 2001 until now, we conducted a national study to
evaluate whether the changes in the screening procedure and
treatment strategy over two decades (e.g. earlier detection,
higher initial T4 dose) have led to the improved development
of patients with CH. We investigated intellectual and motor
outcome and social-emotional functioning in terms of
HRQoL of CH patients born in 1981–1982, 1992–1993, and
2002–2004. The purpose of the present study was to explore
the HRQoL, CoL, social demographical outcomes, and self-
esteem in young adults with CH born in 1981 and 1982, and
compare the results with those of the general (healthy) pop-
ulation. Furthermore, the study examined the influence of
severity of CH on these outcomes.
Patients and Methods
Patients
The complete cohort ofCHpatients born inTheNetherlands in 1981
and 1982 consisted of 136 patients (Table 1). Medical data of these
patients were available at the AcademicMedical Center (AMC) because
of previous studies (8, 18). From the original cohort, four patients had
died, three had moved abroad, and five had severe mental retardation
related to chromosomal abnormalities, or unclassified syndrome with
deafness. Patientswere tested at amean age of 21.5 yr (range 21.0–22.3).
In 2001, the remaining 124 patients were contacted via their physi-
cians and were asked to participate. A total of 82 patients (66%) gave
theirwritten informed consent. Toascertain that patientswere euthyroid
(i.e. TSH, 0.4–4.0 U/ml) at testing, the most recent measurement of
thyroid functionbefore the psychological assessmentswas evaluated; the
T4 supplementation dose was adjusted when TSH was outside its refer-
ence range.
Procedure
All patients were asked to complete the questionnaires, at the AMC
(except for four, who were tested at their local hospitals), under the
supervision of the same psychologist, who was blinded to the patient’s
medical details. The assistance of the psychologist was restricted to ex-
plaining the meaning of difficult words. The description of the nonpar-
ticipants is provided in a previous study (7). The study protocol was
approved by the institutional review board of the AMC.
Measures
TNO-AZLQuestionnaire for Adult’s Health-RelatedQuality
of Life (TAAQoL)
The “TNO-AZL (Netherlands Organization for Applied Scientific
Research) Questionnaire for Adult’s Health-Related Quality of Life”
(TAAQoL) is a validated, generic HRQoL questionnaire for subjects 16
yr and older (19). The questionnaire focuses on health problems in the
past month, and, if present, the well-being in relation to this health
problem is assessed. The TAAQoL comprises 12 scales: gross motor
functioning (e.g. difficulty walking, bending); fine motor functioning
(e.g. difficulty cutting papers or opening a can); cognitive functioning
(e.g. difficulty remembering or concentrating); sleeping (e.g. sleeping
restlessly, lay awake a lot); pain (e.g. backache, pain in neck-shoulders);
social functioning (e.g. talk to others, visit friends); limitations of daily
activities (e.g. difficulties withwork, done less work); sexual functioning
(e.g. had less sex); vitality (e.g. feel energetic, tired); happiness (e.g. feel
joyful, cheerful); aggressiveness (e.g. feel angry, aggressive); and depres-
sive moods (e.g. feel sad or worried). The scale scores are obtained by
adding item scores within scales and transforming crude scale scores to
a 0–100 scale; higher scores indicate a better HRQoL. The Cronbach’s
alphas in the study population were moderate to good for all scales
except the fine motor function scale, which was excluded from analysis.
From the available database from the original TAAQoL study, young
TABLE 1. Characteristics of the 1981–1982 cohort
Etiology Total
Nonparticipants
ParticipantsNot suitable Not willing
Thyroid agenesis 36 2 9 24
Thyroid dysgenesis 59 7 15 37
Thyroid dyshormonogenesis 17 3 6 8
Central CH 19 8 11 0
CH nos 5 4 1 0
Total 136 24 42 69
Four groups are presented: the total group, the group of patients that did not participate divided into patients not suitable or not willing to participate, and the group
that did participate. For each group, the subdivision according to etiological classification is given. nos, Not otherwise specified.
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adults aged 18–25 yr were selected. Adults with a chronic disease in this
population were deleted from this database. This resulted in a norm
population of 201 healthy young adults.
The CoL Questionnaire
The CoL Questionnaire, developed by the Psychosocial Department
of the Emma Children’s Hospital, AMC, assesses the achievement of
developmental milestones of young adults, aged 18–30 yr, who have
grown up with a chronic or life-threatening disease (20). The items con-
cern behaviors that are characteristic of certain age stages, developmen-
tal tasks, and the limitations patients might encounter when they grow
up with a chronic disease. Most questions ask retrospectively whether
(yes, no) and at what age the respondent had achieved certain develop-
mentalmilestones. For this study three scaleswere used, i.e. development
of autonomy, psychosexual development, and social development. A
higher score indicates a more favorable CoL. The questionnaire also
measures sociodemographical outcomes in young adulthood, such as
living situation, education, and employment. The questionnaire covers a
total of 74 items. A comparison group of 274 respondents aged 19–24
yr was available (see Ref. 21 for details).
Thevalidity and the test-retest reliabilityof theCoLscales aregood (20).
The internal consistencies (Cronbach’s ) in the population under study
were small to good: 1) development of autonomy: CH 0.40, comparison
group 0.48; 2) psychosexual development: CH 0.83, comparison group
0.67; and 3) social development: CH 0.76, comparison group 0.71.
Self-Esteem Scale
Self-esteemwas assessedwith theRosenberg Self-EsteemScale (RSE),
a self-administered, 10-item, 4-point scalewith response options ranging
from one (strongly agree) to four (strongly disagree) (22). The scale
measures the self-acceptance aspect of self-esteem or the overall sense of
being capable, worthwhile, and competent. Possible scores range from
10–40. The scoring direction on five negatively phrased items was re-
versed, so a higher score now is indicative of higher self-esteem. For the
study sample, a sufficient Cronbach’s coefficient of 0.89was obtained.
A comparison group of 515 young adults aged 18–25 yr was available
(see Ref. 23 for details).
Statistical analysis
Datawere analyzed using SPSS version 12.0 (SPSS Inc., Chicago, IL).
Before conducting the final analyses, several preparation analyses were
conducted. First, scale scores were computed and missing data imputed
on the basis of the guidelines of the questionnaires. The missing data on
the TAAQoL and RSE were imputed at scale level. In calculation of the
scale scores, one missing item score was allowed for. The missing score
is replaced by themean value of the nonmissing item scores. Themissing
data on the CoL questionnaire were not imputed. Second, the internal
consistencies (Cronbach’s ) of the scales were calculated, and the dis-
tributions of the scale scores were considered.
After the preparatory analyses, univariate ANOVAswere conducted
to test differences between the CH group and healthy controls on the
TAAQoL scales, CoL scales, and RSE, corrected for gender. All CH
patientswere comparedwith thenormdata, and thereafter the severe and
moderate/mild subgroups as well. Comparisons between the severe and
moderate/mild CH subgroups, with respect to their scores on the
HRQoL scales, CoL scales, and RSE, were also made. To adjust for
multiple testing, we used a Bonferroni correction and adjusted the  to
0.004 (0.05/11) for the TAAQoL, 0.016 (0.05/3) for the CoL, and 0.05
(0.05/1) for RSE. For all variables, effect sizes (d) were calculated by
dividing the difference in mean score between all CH patients and com-
parison group by the SD of the scores in the comparison group. We
considered effect sizes up to 0.2, 0.5, and 0.8 to be small, moderate, and
large, respectively (24).
To create a clinically meaningful distinction between young adults
that canbe considered“at risk”or“not at risk” forproblems, twogroups
were formed, based on percentile norms in the healthy population. If this
is done for groups classified by age and gender, differences between the
CH group and norm group are accounted for, and groups can be com-
pared (25). The definition of young adults with problems was based on
the value of the 25thpercentile for all domains of theTAAQoL,CoL, and
the RSE in the norm population. A young adult who scores below the
25th percentile is placed in the quarter of the most impaired population.
To determine whether the CH sample was different from the healthy
population, percentages at risk were compared using 2 tests.
To gain detailed insight into the CoL of CH patients, differences on
item level (milestones) were also calculated on the social development
scale of the CoL questionnaire because there was a significant difference
on this scale between the CH and comparison group. 2 tests were con-
ducted at the frequency distributions of the individual items of this scale.
Finally, 2 tests were conducted to investigate differences in educa-
tional level (low,middle, andhigh),1 special education at primary school,
living situation, and marital status. We used a significance level of P 
0.01 to compensate for multiple testing.
Results
Patient characteristics
A total of 82 CH patients (66% of the original cohort) gave
theirwritten informed consent, and their initial thyroidhormone
levels and treatment modality were recorded. Of this group, 13
patients were excluded from the study because of central CH
(n  1), because treatment was never initiated (n  1), an ex-
ceptionally late (i.e.  4 yr of age) start of treatment (n  5), a
discontinuation of treatment at a young age (n 4), or because
the patients did not return the questionnaires (n  2). The re-
maining 69 patients, 51% of the original cohort (total CH
group), were classified into two subgroups according to an ar-
bitrarily chosen cutoff level for severity of postnatal hypothy-
roidism: “severe CH,” with initial T4 less than 2.3 g/dl (30
nmol/liter); and “moderate and mild CH,” with initial T4 more
than or equal to 2.3 g/dl (30 nmol/liter).
The baseline characteristics of the participatingCHpatients are
giveninTable2.Ofthe69patients (55females,79%),34hadsevere
CH, and 35 hadmoderate/mild CH. Themedian age of start of T4
supplementationwas28d for the total group.The intelligencequo-
tient (IQ) scores of the participatingCHpatients are given in Table
2. For all details, we refer to a previous publication (7).
Comparison with the healthy population
HRQoL
HRQoL of the total CH group appeared to be significantly
worse (P 0.004) than the healthy Dutch population on seven of
the 11 scales of the TAAQoL: cognitive functioning, F (1.266) 
61.528,P0.0001; sleeping,F (1.266)8.511,P0.004); pain,
F (1.266)  15.527, P  0.0001); daily activities, F (1.265) 
10.039, P  0.0002); vitality, F (1.253)  9.273, P  0.0001);
aggressiveness, F (1.253)  10.803, P  0.001); and depressive
moods, F (1.254)  13.745, P  0.0001. These differences were
moderate to large [effect sizes (d) ranged from 0.6–1.3, Table 2)]
HRQoL of the severe CH group appeared to be significantly
worse (P 0.004) than the healthyDutch population on six of the
1 Low: primary education, technical and vocational training, lower and middle general
secondary education; Middle: middle vocational education, higher general secondary ed-
ucation, preuniversity education; and High: higher vocational education, university.
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11 scales of the TAAQoL: cognitive functioning, F (1.233) 
36.079,P0.0001; pain,F (1.266)15.527,P0.0001; vitality,
F (1.224)  7.816, P  0.004; social functioning, F (1.230) 
8.750, P 0.004; aggressiveness, F (1.224) 11.353, P 0.004;
and depressive moods, F (1.225) 12.505, P 0.0001.
HRQoL of the moderate/mild CH group appeared to be sig-
nificantly worse (P 0.004) than the healthy Dutch population
on four of the 11 scales of the TAAQoL: cognitive functioning,
F (1.233)36.097,P0.0001; sleeping,F (1.233)6.953,P
0.0001; pain, F (1.233)  10.275, P  0.004; and vitality, F
(1.225)  8.719, P  0.004.
No significant differences were found between the CH pa-
tients and healthy Dutch population on three of the 11 scales on
the TAAQoL (gross motor functioning, sexual functioning, and
happiness).
CoL
The total CH group and the severe CH group scored signif-
icantly loweronone scale of theCoL than the comparisongroup:
social development, total CH group, F (1.334)  6.191, P 
0.013; severe CH group, F (1.302)  6.557 (Table 3). This dif-
ference was small: effect size (d)  0.3. No differences were
found for the autonomy scale and psychosexual development
scale.
With respect to the milestones of social development, we
found significant differences between the CH patients and the
reference group on two of the 12 milestones (Table 4). A lower
percentage of CH patients than the comparison group had been
a member of a sports club for at least 1 yr during primary school
and secondary school.
No statistically significant differences between CH and the
TABLE 2. Characteristics of the subgroups with different severity of CH
Severe CH Moderate/mild CH
No. of patients (male/female) 34 (7/27) 35 (8/27)
Initial T4 in ng/dl (95% CI)
a 1.2 (0.9–1.4) 5.6 (4.6–6.7)
Initial T4 in nmol/liter (95% CI)
a 15.0 (11.9–18.2) 72.7 (59.6–85.8
Median age at start of T4 (range) 26 d (8–47) 39 d (4–293)
Mean IQ scores of the CH patients at 21.5 yr of age
recently published in Ref. 7
Severe Moderate Mild
Full-scale IQ 91.3 (86.3–96.3) 99.1 (91.1–107.1) 101.3 (95.7–106.9)
Verbal IQ 92.9 (88.1–97.8) 97.8 (89.2–106.3) 101.8 (96.1–107.5)
Performance IQ 90.4 (85.2–95.6) 101.3 (94.8)–107.7) 100.4 (94.7–106.1)
CI, Confidence interval.
a Reference range for T4 in children aged 2–6 wk, 6.5–16.3 g/dl (84–210 nmol/liter).
TABLE 3. Mean scores, SD values, and differences between CH patients and comparison group on HRQoL, CoL, and self esteem,
as a function of group, corrected by gender
Total CH Severe CH Moderate/mild CH Comparison group Effect size
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Total
TAAQoL n  69 n  34 n  35 n  201
Gross motor functioning 92.4 (14.0) 90.7 (13.7) 93.9 (14.3) 96.8 (9.1) 0.5
Cognitive functioning 65.8 (27.4)a 64.0 (27.6)a 67.5 (27.4)a 89.0 (17.2) 1.3
Sleeping 71.5 (25.3)b,c 76.4 (24.6) 67.0 (25.4)a,b 81.6 (19.1) 0.5
Pain 74.4 (19.8)a,b 74.2 (21.1)b,c 74.5 (18.9)c 84.7 (16.0) 0.6
Social functioning 86.6 (18.2) 82.2 (20.3)c 90.7 (15.0) 91.0 (15.8) 0.3
Daily activities 77.3 (25.8)c 78.4 (25.9) 76.3 (26.1) 86.1 (19.1) 0.5
Sexual functioning 84.6 (24.8) 87.9 (23.9) 81.3 (25.6) 91.7 (17.9) 0.4
Vitality 56.5 (21.8)a,b 56.6 (22.1)b,d 56.3 (22.0)b,c 70.1 (19.5) 0.7
Happiness 70.2 (20.0) 67.3 (21.4) 73.2 (18.3) 73.2 (18.9) 0.2
Aggressiveness 78.9 (22.8)b,c 76.2 (20.7)c 81.6 (24.7) 88.2 (15.5) 0.6
Depressive moods 70.8 (23.4)a,b 68.5 (23.4)a 73.0 (23.6) 81.9 (15.5) 0.7
CoL n  69 n  34 n  35 n  274
Autonomy development 9.0 (1.4) 8.8 (1.2) 9.2 (1.6) 9.4 (1.5) 0.3
Psychosexual development 7.2 (1.3) 6.8 (1.6) 7.5 (0.9) 7.2 (1.2) 0.0
Social development 20.25 (2.9)d 20.0 (2.9)d 20.6 (2.9) 21.2 (2.5) 0.4
Self-esteem n  63 n  31 n  32 n  515
Self-esteem 29.9 (4.7)b,c 29.0 (4.8)b,c 30.8 (4.4)b 32.1 (4.7) 0.5
Higher score represents a better HRQoL, CoL, and self-esteem. d, Effect size.
a P  0.0001 difference between CH patients and comparison group (based on univariate F tests according to ANOVA, TAAQoL scales by group and gender).
b Univariate effects were found on gender (P  0.01).
c P  0.005 difference between CH patients and comparison group (based on univariate F tests according to ANOVA, TAAQoL scales by group and gender).
d P  0.01 difference between CH patients and comparison group (based on univariate F tests according to ANOVA, TAAQoL scales by group and gender).
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comparison group were found in the number of patients still
living with their parents or in marital status. In addition, no
significant difference was found with respect to current educa-
tional level and in patients receiving special education at a pri-
mary school compared with the comparison group (Table 5).
Self-esteem
CH patients in the total and severe CH group appeared to
have a significantly lower self-esteem than the comparison
group: total CHgroup,F (1.572)5.224,P0.005; and severe
CH group, F (1.542)  8.513, P  0.004) (Table 3). These
differences had moderate effect sizes (d  0.5).
Within-group differences according to severity
There were no significant differences found between the se-
verity groups for HRQoL, CoL, and self-esteem (Table 3).
Prevalence of young adults with CH at risk
Table 6 shows the percentages of young adults at risk for all
impaired HRQoL, CoL, and self-esteem domains. 2 tests com-
paring the CH patients with healthy controls on HRQoL, CoL,
and self-esteem showed significant differences for six scales of
the TAAQoL. The total group of CH patients showed signifi-
cantly higher percentages of patients at risk forHRQoL than the
comparison group on five scales of theTAAQoL (cognitive func-
tioning, social functioning, daily activities, vitality, and depres-
sive moods), ranging from 41–68%. In the severe group, CH
patients were considered at risk for problems on six scales of the
TAAQoL (grossmotor functioning, cognitive functioning, social
functioning, aggressiveness, vitality, and depressive moods),
ranging from42–70%. In addition,CHpatients in themoderate/
mild CH group were only considered at risk on two scales of the
TAAQoL (sleeping, cognitive functioning), ranging from
54–66%.
Discussion
To our knowledge, this is the first study describing the develop-
mental and HRQOL consequences in early treated young adult
TABLE 4. Milestones of social development (CoL questionnaire) CH patients vs. comparison group
Social development CH (n  69) Comparison (n  297)
At least 1-yr membership in a sports club, primary school
Yes 73.9a 86.8
No 26.1 13.2
No. of friends in first-third grade, primary school
4 40.6 27.9
4 59.4 72.10
No. of friends in fourth-sixth grade, primary school
4 36.2 25.3
4 63.8 74.7
Best friend, primary school
Yes 77.9 74.1
No 22.1 25.9
Most of the time playing with.., primary school
Friends 85.3 89.3
Brothers and/or sisters, parents, on your own 14.7 10.7
At least 1-yr membership in a sports club, secondary school
Yes 55.9b 77.4
No 44.1 22.6
No. of friends, secondary school
4 36.2 25.3
4 63.8 74.7
Best friend, secondary school
Yes 72.5 71.3
No 27.5 28.7
Belonging to a group of friends, secondary school
Yes 70.6 82.7
No 29.4 17.3
Leisure time, mainly with .., secondary school
Friends 76.1 85.8
Brothers and/or sisters, parents, on your own 23.9 14.2
Going out to a bar or disco, secondary school
Sometimes/often 75.4 86.2
Never 24.6 13.8
At least 1-yr membership in a sports club, after secondary school
Yes 42.0 49.1
No 58.0 50.9
a P  0.001 based on 2 test.
b P  0.01 based on 2 test.
2658 van der Sluijs Veer et al. Quality of Life of Young Adults with CH J Clin Endocrinol Metab, July 2008, 93(7):2654–2661
patients with CH using validated and reliable instruments. We
have shown that having CH does negatively influence the
HRQoL, social development, and self-esteem. However, the so-
ciodemographical outcomes and their final educational level un-
til now did not differ from that of the normal population.
This study shows that patients with CH born in 1981–1982
do not experience more problems with autonomy development
and sexual functioning, and they have similar feelings of happi-
ness as the healthy Dutch population controls. Despite these
positive findings,CHhas anegative impact on thedaily life of the
patients. They experienced more problems concerning cognitive
and social functioning, pain, daily activities, aggressiveness, self-
esteem, and they appeared to be less vital and more depressed
compared with the healthy Dutch population. To add clinical
meaning to these differences, we divided the young adults into
two groups, one at risk for an impaired HRQoL, CoL, and self-
esteem,andonenot at risk.Thisdivision shows that youngadults
with CH, especially in patients with severe CH, are more often
at risk for HRQoL impairment. The definition of young adults
as being at risk was based on the value of the 25th percentile of
all scales in the norm population. There is no gold standard for
good or bad HRQoL, CoL, and self-esteem, however, this def-
inition is considered to be a suitableway to differentiate between
individuals with higher scale scores from individuals with lower
scale scores (25).
The most salient result is that CH patients reported a con-
siderable lower HRQol on the cognitive functioning scale of the
TAAQoL, also presented in a high percentage of patients con-
sidered at risk. Cognitive functioning was assessed as the occur-
rence of problems with attention and memory, and if such a
problemwas indicated, thedegree towhich thepatient is actually
bothered by that problemwas assessed subsequently. The lower
scores on the cognitive function scale of the TAAQoL are in line
with the results of neuropsychological studies, which showed
that children and young adults with CH scored significantly
poorer on overall attention and had more problems with mem-
ory than controls (26–29). Our results indicate that problems in
cognitive functioning troublemostCHpatients andhamper their
daily life.
As expected, severeCHpatients aremore at risk for problems
with gross motor functioning than patients with moderate/mild
CH. This is consistent with our recent findings that the total CH
TABLE 6. Percentage of patients with CH at risk for HRQoL impairment
Total CH Severe CH Moderate/mild CH Comparison group
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
TAAQoL n  68 n  33 n  35 n  201
Gross motor functioning 32% 42%b 23% 25%
Cognitive functioning 68%a 70%a 66%a 25%
Sleeping 43% 31% 54%b 25%
Pain 46% 48% 20% 25%
Social functioning 46%b 58%a 34% 25%
Daily activities 41% 39% 43% 25%
Sexual functioning 34% 25% 40% 25%
Vitality 44%b 50%b 38% 25%
Happiness 29% 36% 15% 25%
Aggressiveness 47%a 57%b 38% 25%
Depressive moods 46%b 50%a 41% 25%
CoL n  69 n  34 n  35 n  274
Autonomy development 39% 41% 37% 25%
Psychosexual development 26% 35% 17% 25%
Social development 30% 36% 25% 25%
Self-esteem n  69 n  33 n  35 515
Self-esteem 27% 36% 19% 25%
Twenty-fifth percentiles of healthy young adults are not exactly 25% due to distribution of scale scores. Percentiles approach 25th, ranging from 18th-31st percentile.
a P  0.0001 2 test in comparison with healthy children.
b P  0.004 2 test in comparison with healthy children.
TABLE 5. Percentages and differences between CH group
and comparison group with respect to living situation and
employment status
% CH
(n  69)
% Comparison
(n  297)
Living with their parents
Yes 43.5 41.2
Marital status
Married/living together 24.2 18.8
Single 75.8 81.2
Special education at primary school
Yes 13.0 5.4
Educational levela
Low 29.9 30.4
Middle 65.7 61.8
High 12.0 7.8
Educational levelb
Low 14.5 17.2
Middle 46.4 38.0
High 39.1 44.8
P  0.01 based on 2 test. High, Higher vocational education, university; Low,
primary education, technical and vocational training, lower and middle general
secondary education; Middle, middle vocational education, higher general
secondary education, preuniversity education.
a Highest level completed.
b Highest level completed/or ongoing study.
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group born in 1981/1982 had substantial motor problems (7).
This is also in line with the findings on the items of the social
development scale of the CoL questionnaire, which showed that
CHpatients reported a lower level of participation in sport clubs.
Although more significant differences between the severity
group and the comparison group than the moderate/mild CH
group comparedwith the healthy populationwere found,we did
not find significantwithin-groupdifferences on severity forCoL,
HRQoL, or self-esteem. It may be considered that the existence
of a chronic disease as such, regardless of its severity, influences
functioning in daily life.
The negative consequences of CH on the HRQoL, social de-
velopment, and self-esteemmight also be explained by the fact of
living with a chronic disease. CH affects the patient’s daily life
because of the daily T4 administration, the need of regular T4-
dose adjustments, frequent T4 and TSH measurements, con-
sciousness of having a chronic disease, and sometimes the need
of adjuvantmedical care such as speech training and physiother-
apy. It is also possible that parents of a child with CHweremore
protective, which resulted in less stimulation of social develop-
ment. In addition, the cognitive and motor problems of CH pa-
tients may have affected their social life, self-esteem, and emo-
tional functioning. From this study and our previous study (7),
it is apparent that CHpatients seem to be vulnerable in this area.
Besides, one has to keep in mind that a suboptimal thyroid hor-
mone statemay affect well-being.Whereas the goal of long-term
T4 treatment is to maintain euthyroidism, this remains challeng-
ing because of the continuous need to adapt T4 dose in a growing
child and the need of treatment compliance. Recently, it has been
shown that differences in free T4 and TSH concentration, even
within the reference range, may be a determinant of psycholog-
ical well-being in treated hypothyroid patients (30).
The strength of our study is that all patients were treated by
pediatricians who followed the national guidelines and that at
psychological assessments, all patients had plasma TSH concen-
trations within the reference range.
There are some limitations in the present study that need to be
mentioned. First, “course of life” encompasses more than the
achievement of developmental milestones and encompasses
more accomplishment during childhood than we have been able
to assess with the questionnaire. It is the only (Dutch) question-
naire concerning this issue, and test-retest reliability has proved
to be satisfactory (20). However, the internal consistency of the
autonomy scale is small, probably because the items concern
diverging aspects of autonomy. The disadvantage of using scales
with low internal consistency is that detecting differences be-
tween groups ismore difficult. Considering our findings, this did
notapply. Second,CHpatientsdescribed in this studydiffer from
more recently diagnosed patients because the screening and
treatment strategy has been changed over the past two decades
(e.g. earlier detection, higher initial T4 dose). Therefore, we need
to be cautious in generalizing our results toward more recently
diagnosedCHpatients. In addition, it is important to investigate
the HRQoL, CoL, social demographical outcomes, and self-es-
teem in more recent cohorts. Another limitation is the loss of
subjects from the original cohort, which restricts the represen-
tativity of the current sample. Besides, we have no information
about the socio-economic status,we clarified the etiologyof both
the excluded patients and the patients not willing to participate
(Table 1). At last we should take notice of the use of different
questionnaires of which norm data were acquired in different
studies. This should be considered when comparing the data.
The findings of the study have implications for future re-
search. It is important to study cognitive functioning in more
detail, e.g. to determine attention and memory of CH patients.
Interventionprograms that improvememory andattention func-
tioning might thereafter be offered to particular individuals.
A remarkable result in the present studywas that CHpatients
were not different in educational level compared with controls.
Most patients were 21 yr of age at testing. Therefore, most pa-
tients have not yet completed their education at the moment of
testing. For that reason, it is unclear whether CHpatients will be
able to function on the same level in society (after completion of
their education) as their healthy peers. For future research this is
an important aspect to consider when testing adult patients who
already fulfill a certain role in society.
Because CH patients appeared to be less vital and more de-
pressed compared with the healthy Dutch population, it seems
interesting to study the relation between CH, and anxiety and
depression in more detail. From a developmental, psychological
point of view, the fulfilling of age-specific developmental tasks in
childhood is of great importance for adjustment in adult life (14,
31). For this reason it is important todirect future researchon the
predictors of a hampered social development to be able to detect
the children and adolescents who are at risk at an early stage.
Communication about problems in clinical practice should
be studied in more detail to get insight into whether problems
are adequately assessed. Computer-scored individual mea-
surement of HRQoL, to inform the physician about the pa-
tient’s HRQoL (32, 33), should be considered for clinical
practice. The computer output, usually a graphical summary
of HRQoL outcomes, assists the physician to focus at the
HRQoL domains that correspond with the patient’s needs.
Using HRQoL measurement can facilitate patient-physician
communication and can identify patients with the greatest
needs so that a focused action, e.g. referring to other health
care providers, can be performed.
In summary,weconclude that youngadultswithCHreported
a lower HRQoL and had a lower self-esteem compared with
healthy peers. CH patients also had a delayed social develop-
ment. Therefore, it is important for parents and clinicians to
encourage childrenwithCHto continuepeer-related activities as
much as possible to stimulate their social performance and, with
that, their self-esteem. An awareness about patients’ HRQoL
and possible gaps in the CoL can be useful in clinical practice
because it enables health care providers to select and adjust
coaching programs to aim at a most favorable CoL in these pa-
tients, throughout their development. Most of all, our findings
add to the evidence for cognitive problems in relation to CH.
Health care physicians should be observant for cognitive prob-
lems and refer for more detailed psychosocial assessment if
necessary.
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